Critical event management provider OnSolve stated on Wednesday that the public health authorities are using its CodeRED product to communicate with citizens and first responders regarding the COVID-19 vaccine availability and immunization logistics across the US.
The company has established a public advisory to help government officials at the local, state and federal levels, as well healthcare organizations, including hospitals, maximize their efforts to effectively and safely organize their COVID-19 vaccination effort.
Currently, nearly 200 communities are using the company's CodeRed to manage the sharing of information related to COVID-19 vaccine deployment and nearly 640,000 messages related to vaccine deployment have been sent. They are leveraging CodeRED's rapid, tailored critical communications capabilities and easy integration with other emergency management solutions for this vital public health project.
In conjunction, Coles County Health Department in Charleston, Illinois will use the company's CodeRED emergency notification solution to communicate critical information related to COVID-19 vaccine deployment in the area.
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100